FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
Consumer Update |
FDA is tightening the potency specifications for levothyroxine sodium, used to treat underactive thyroid glands and other thyroid conditions, to ensure that the drug retains its potency over its entire shelf life. The shelf life is the length of time a drug can be stored before it degrades to unacceptable levels.
A healthy, functioning thyroid gland is critical to regulating a person's overall metabolic function, which impacts a host of other bodily functions.
FDA is taking this recent action in response to concerns that the drug's potency may deteriorate prior to its expiration date. The change will help improve the quality of the product so that consumers receive the level of medication needed to treat their thyroid disorders. Levothyroxine sodium products are used by over 13 million patients.
Consumers can also help maintain the potency of their medications by storing them in a dry place at room temperature and avoiding humid, hot environments such as bathrooms, which speed deterioration.
Thyroid Medications: Q & A with Mary Parks, M.D.
www.fda.gov/consumer/features/thyroid010208.html
FDA Press Release
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01717.html
Levothyroxine Sodium Product Information
http://www.fda.gov/cder/drug/infopage/levothyroxine/default.htm
Date Posted: October 12, 2007